Kornimate/medical-research-clean huggingface dataset:
the impact of breath exercises by telemedicine in patients aged 8-18 years with a diagnosis of asthma

Conditions: Allergic Asthma

Summary: the goal of this randomized, placebo controlled study is to evaluate the effect of respiratory exercises on asthma attack frequency, symptom and medication scores and quality of life of children with a diagnosis of asthma. participants will be asked to perform respiratory exercises described at once in hospital at home regularly. control group will comprised children with asthma without respiratory exercises.

at the beginning of the study anthropometric measurements, basal respiratory function assessment, drugs, demographic information, allergen sensitivity, asthma control levels and quality of life scales will be documented. patients will be randomly divided into two groups; one group following respiratory exercises and relaxation exercises and the other following only relaxation exercises. both groups will be called regularly to remind the exercises. the spirometric tests and asthma control forms will be reevaluated at the 3rd and 6th month at hospital. peak flow meters will be given to patients to document pef values during study.

Eligibility criteria:
inclusion criteria: clinical diagnosis of allergic asthma allergic asthma severity step 1 or step 2 - exclusion criteria: asthmatic children more severe than step 2 other comorbid disorders involving respiratory system or neuromusculatory disorders -

Keywords: allergy, asthma, respiratory exercises, children
a 16 week study to evaluate the effect on insulin sensitivity of valsartan (320 mg) and hydrochlorothiazide (25 mg) combined and alone, in patients with metabolic syndrome

Conditions: METABOLIC SYNDROME; HYPERTENSION; PRE-HYPERTENSION

Summary: the metabolic syndrome is a classification for patients with a constellation of risk factors which may include abdominal obesity, hypertension, elevated blood lipids and sugar. three or more of these factors together constitute the metabolic syndrome and place these patients at a greater risk for the development of diabetes and cardiovascular diseases. the purpose of this study is to determine whether two common drugs to lower blood pressure, whether used separately or in combination, have different effects on blood sugar levels in patients diagnosed with the metabolic syndrome.


Eligibility criteria:
inclusion criteria: * waist circumference: males \> 40", females \> 35 " * mssbp ≥ 130 mmhg but ≤ 160 mmhg and a msdbp ≥ 85 mmhg but ≤ 100 mmhg * at least one of the following criteria: - fasting plasma glucose between 5.9 and 6.9 mmol/l; - serum triglycerides \> 150 mg/dl; - ldl cholesterol: - \< 40 mg/dl males; - \< 50 mg/dl females exclusion criteria: * mssbp\> 180 mmhg or msdbp \> 110 mmhg * inability to discontinue all prior antihypertensives for a period of 4 weeks. * history of diabetes * history of stroke, transient ischemic attack or myocardial infarction. * significant weight change \> 10 lbs during screening period * patients taking a diuretic for 3 months prior to screening. other protocol-defined exclusion criteria may apply.

Keywords: metabolic syndrome, valsartan, hydrochlorothiazide, hypertension,
post-eradicate - a long term follow up of subjects that completed the eradicate study (nct 02097303)

Conditions: Prostate Cancer Metastatic

Summary: this is a long term follow up study to eradicate, an open label study designed to examine the effects of radium ra 223 dichloride with concurrent administration of abiraterone acetate plus prednisone castrate-resistant (hormone-refractory) prostate cancer subjects with symptomatic bone metastasis.

this is a long term follow up study to eradicate, an open label study designed to examine the effects on concurrent administration of radium ra 223 dichloride and abiraterone acetate plus prednisone in subjects with symptomatic castrate resistant prostate cancer and with bone metastases. 31 subjects completed all study visits in the eradicate study, and were thus evaluable. all 31 subjects will be asked to participate in this long term follow up study which will evaluate overall survival, subsequent additional prostate cancer therapies and medications, radiographic changes and sse's (symptomatic skeletal events), incidence of bone marrow failure, and diagnosis with secondary malignancies. living subjects will be evaluated at least 12 weeks after their last dose of radium ra 223 dichloride and at each subsequent clinic visit. deceased subject's data will be obtained retrospectively, from 12 weeks after the eradicate end of treatment visit and prospectively through the date of death. the total duration of the study is expected to be 48 months

Eligibility criteria:
inclusion criteria: * eligible subjects are adults over the age of 18 with mcrpc that completed the eradicate study. the living study subject or legally authorized representative must be able to understand and sign the written informed consent form. exclusion criteria: * a living study subject or his legally authorized representative are not able to understand or willing to sign the written informed consent form.
identify biomarkers of tobacco exposure and nicotine uptake from juul 5% in adult smokers

Conditions: Nicotine Dependence, Other Tobacco Product; Tobacco Use; Smoking, Tobacco

Summary: the juul 5% electronic nicotine delivery system (ends) is being studied as an alternative to combustible cigarette use. this study aims to find out how much nicotine is in the blood and urine of healthy adult subjects after using three juul 5% ends compared to smoking usual brands of combustible cigarettes and stopping smoking.

this study will serve as a clinical evaluation of the exclusive use of selected juul ends, with the purpose of gaining an understanding of toxicant exposure.

Eligibility criteria:
key inclusion criteria: 1. healthy, adult, male or female smoker, 21 to 65 years of age. 2. has been a smoker for at least 12 months prior to screening. 3. currently smokes an average of 10 cigarettes each day. 4. has a positive urine cotinine (≥ 500 ng/ml). 5. has an exhaled carbon monoxide (co) \> 12 ppm. 6. a female subject of childbearing potential must have been using contraception and agree to continue using it through completion of the study: 7. provides voluntary consent to participate in this study documented on the signed informed consent form (icf). key exclusion criteria 1. has a history or presence of clinically significant conditions. 2. has a body mass index (bmi) \> 40 kg/m2 or \< 18 kg/m2 at screen 3. has a history of drug or alcohol abuse 4. has an estimated creatinine clearance \< 80 ml/minute 5. if female, the subject is pregnant, lactating, or intends to become pregnant during the time period from screening through the end of study. 6. has used nicotine-containing products other than manufactured cigarettes within 14days of screening. 7. is planning to quit smoking during the study, planning to quit within 3 months following day 1
prevention of postsurgical chronic pain in children and adolescents (prevendol)

Conditions: Chronic Postsurgical Pain; Chronic Post-surgical Pain; Chronic Postoperative Pain; Chronic Post-operative Pain

Summary: chronic postsurgical pain is a health problem with a great societal impact: approximately 20% of all children and adolescents undergoing surgery will develop chronic pain. importantly, the risk and protective factors that are known (e.g., anxiety, catastrophizing, pain beliefs and pain coping) are modifiable, thus there is a huge potential for the development of both preventive and protective programs to avoid the transition from acute to chronic pain or reduce the impact in the lives of patients when it has already developed.

the main objective of this project is to develop and test a program to prevent the development of chronic postsurgical pain in children and adolescents undergoing surgery in order to improve their quality of life (and that of their families). that program will be implemented in a mobile application. this proposal will be implemented in 3 phases: 1. development of the preventive program of chronic postsurgical pain and its implementation in a mobile application 2. usability test of the mobile application 3. clinical trial to test the effectiveness of the preventive program

Eligibility criteria:
inclusion criteria: 1. having to undergo surgery 2. being between 8 and 18 years old; 3. having signed the informed consent 4. having an asa risk between i and iii exclusion criteria: 1. not being able to understand spanish 2. having a physical and/or cognitive impairment that interferes with understanding the instructions and handling of the application (e.g., moderate to severe intellectual disability, blindness) 3. participating in another clinical trial 4. undergoing an urgent surgical intervention 5. being hospitalized in intensive care due to the need for ventilation or hemodynamic support or other complications 6. having an asa risk of iv 7. not having signed the informed consent
analysis of microbiota variations in industry workers working different shifts and impact of a nutritional intervention

Conditions: Dysbiosis

Summary: shift workers are a growing population. it is well established that these workers face an increased risk of developing chronic diseases, but the underlying mechanisms remain debated. various factors such as internal circadian desynchronization, unhealthy lifestyle behaviours, and lack of sleep interact in complex ways. recently, it has been suggested that the gut microbiota (gm) may play an important role in this increased risk. the goal of this study is to describe the variations of the gm composition in shift workers across three different rotating weekly shifts (morning, afternoon, night) and to measure the impact of a 3- week walnuts supplementation intervention consisting in a controlled experimental study. therefore, we propose a 6-weeks study including an observational and an experimental part. first, in the observational part, we will compare the gut microbiota of shift workers across three shifts (morning, afternoon and night). in the second part of the study, participants will add to their usual intakes a daily serving of nuts (30g). again, we will compare the gut microbiota composition across the three types of shifts. during the study, participants will record their food intake, sleep and defecation time. we will also monitor their blood glucose levels continuously during the 4 first weeks of the study.


Eligibility criteria:
inclusion criteria: * working 3x8 shifts (weekly rotations between am, pm and n shifts) for at least 3 months prior to the study * no anticipated changes in shift work planning * no prebiotics or probiotics supplements. exclusion criteria: * antibiotic and/or immunomodulator use in the last 3 months or during the study * change in medication during the last month or during study * inflammatory bowel disease or important gut surgery * nuts allergy * major digestive tract surgery.

Keywords: gut microbiota
retrospective observational study of italian cohort of lymphoma patients (retro-lymph)

Conditions: Lymphoproliferative Syndrome, Autoimmune; Lymphoma

Summary: observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between january 1980 and september 2021

observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between january 1980 and september 2021. study objectives are to enrich the data on the prognostic role of clinical and epidemiological factors associated with clinical and epidemiological data of patients; * to identify the factors that affect the evolution of the disease, such as lifestyle and occupational factors, as well as the type of treatment; * to provide a platform for future research projects; * description of the various therapies that have occurred over time, duration of treatment, causes of interruption of treatment, responses; * description of the adverse events / safety of the various therapies for lymphoma and lymphoproliferative syndromes; * patient survival. descriptive analyses will be conducted by tabulating frequency distributions and percentages and mean and median values, standard deviations, quartiles and extreme values for continuous variables. progression-free survival, disease-free survival and overall survival will be examined using kaplan-meier point estimates

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years of enrollment * diagnosis of lymphoma or lymphoproliferative syndrome between january 1980 and september 2021 * signature of the informed consent form where applicable exclusion criteria: * none
prevention of acute kidney injury through biomarker-guided nephrological intervention

Conditions: Acute Kidney Injury

Summary: this study examines the clinical relevance of early biomarkers to detect and prevent acute kidney injury. high-risk patients for developing acute kidney injury will be screened at initial presentation (emergency department and intensive care unit) for timp2xigfbp7. in case of elevated readings patients will be randomized in two arms: the control group will be treated with standard care, the intervention group will receive an early nephrologic consultation.

this study examines the impact of an early biomarker-guided intervention on the development of acute kidney injury (aki). new biomarkers indicate kidney damage in an early stage before developing acute kidney injury according to aki kidney disease improving global outcomes (kdigo) definition is detectable. the investigators want to test if it's possible to prevent aki based on elevated urinary biomarkers. eligible patients will be randomly assigned to two groups, a control and an intervention group by an early nephrologic consultation. the interventional group will receive an early preventive nephrologist consultation additionally to standard care.

Eligibility criteria:
inclusion criteria: * no acute kidney injury stage ii-iii (according to aki kdigo definition) * urinary biomarker levels above cut-off * inpatient treatment * age ≥18 years * informed consent or presumed will exclusion criteria: * existing acute kidney injury stage ii-iii (according to aki kdigo definition) * age \< 18 years * end stage renal disease (esrd), existing renal replacement therapy * pregnancy * withdrawal of consent * missing presumed will
high-dose intravenous vitamin c (hdivc) as adjuvant therapy in critical patients with positive covid-19. a pilot randomized controlled dose-comparison trial.

Conditions: Covid19

Summary: the objective of this study is to evaluate the impact of this hdivc therapy in the first treatment of symptomatic covid-19 patients in a time period of one week.

we consider that treatment with high doses of injectable vitamin c hdivc could have a positive impact as an adjunct on the immunity of patients with covid while reducing the possibility of worsening their clinical picture. similarly, we wish to evaluate the efficacy of this treatment, for one week, in patients hospitalized in the icu, in order to reduce the inflammatory burden and reduce hospital stay.

Eligibility criteria:
inclusion criteria: * adult patients with consent, adult men or women, age ≥ 18 years. * laboratory confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assays; and/or clinical findings suggesting infection. * hospitalized with a sars-cov-2 infection of any duration. * ability to provide an informed consent signed by the study patient or a legally acceptable representative. * willingness and ability to comply with the procedures/evaluations related to the study. * have an oxygen saturation (sao2) of 94% or less while breathing room air; or a ratio between the partial pressure of oxygen (pao2) and the fraction of inspired oxygen (fio2) (pao2: fio2) equal to or less than 300 mg. hg. (who defines pafi less than or equal to 250; being mild: 200-300; moderate: 100-200; severe: 100 or less. * normal kidney function: (creatinine 0.7 mg / dl for men or 20 to 200ng / ml and 0.6 to 1.1 mg / dl for women or 15-150 ng / ml); urinary output greater than or equal to 1 cc / kg / hour; glomerular filtration rate greater than 30 cc / min). * without chronic kidney disease (ckd) defined by stage ii or higher according to the kidney disease improving global outcomes (kdigo) classification. exclusion criteria: * age \<18 or pregnant or lactating woman. * allergy to vitamin c. * severe liver failure. * egfr ≤ 30 ml / min / 1.73 m2 (defined by the ckd-epi scr formula). * history of any organ transplants requiring treatment active immunosuppressant that may interfere with kidney function. * if you required cardiopulmonary resuscitation (cpr) within 14 days, and/or dnr orders (do not resuscitate) dni (do not intubate). * if death is considered imminent or unavoidable during this admission, and the treating physician, patient, or surrogate decision-maker is not engaged in active treatment. * be on dialysis (either acute or chronic) or need dialysis imminent at the time of enrollment. * patients with known hiv infection. * patients with a known or suspected history of nephropathy due to oxalate or hyperoxaluria, scurvy, chronic iron overload, deficiency by g-6pd. * patients with known hemochromatosis.

Keywords: vitamin c- covid-19
immunochromatography versus microscopy for diagnosis of entamoeba histolytica/dispar infection.

Conditions: Dysentery Amebic

Summary: amoebiasis, an infection by the protozoan parasite entamoeba histolytica is globally considered as the third leading parasitic cause of human mortality besides malaria and schistosomiasis. it is estimated that e. histolytica may infect half a billion people annually. moreover, it was estimated that 100,000 patients per year died due to the clinical complications of the disease. laboratory diagnosis of e. histolytica/dispar is usually achieved by microscopic detection of trophozoites or cysts in stool samples. microscopy is time consuming and requires an experienced observer to identify the organism. furthermore, it must be performed on three stool samples to increase sensitivity leading to decreased patient compliance and delay in the final diagnosis. therefore, a few the commercially available copro-antigen assay have been developed for e. histolytica/dispar diagnosis including the enzyme immunoassay and non-enzymatic immunochromatographic (ict) assays that do not depend on microscopy skills and increase laboratory efficiency by reducing time and cost. the aim of the study is: 1. to evaluate the efficacy of commercially available rapid immunochromatographic copro-antigen assay (rida® quick entamoeba) in comparison with conventional microscopic examination for the diagnosis of e. histolytica /dispar infection. 2. to estimate the prevalence of e. histolytica /dispar infection in outpatients in sohag.


Eligibility criteria:
inclusion criteria: * patients complaining of dysentery or diarrhea with any age \& sex groups. exclusion criteria: * patients taking amoebicidal drugs.

Keywords: dysentery diarrhea entamoeba histolytica dispar
a multi-center trial of single-branched stent graft system to treat aortic dissection

Conditions: Distal Aortic Dissection

Summary: aim:castor is a novel single-branched stent graft system for endovascular repair of aortic arch dissection. this is a prospective, one-arm, open, multi-center, pre-market study of castor stent to evaluate its efficacy and safety in treatment of aortic dissection. number of patients: 70 patients will be included and undertaken endovascular repair with castor stent. follow-up: 1.aortic computed tomographic angiography (cta) examination 6 and 12 months after the surgery 2.telephone or clinical follow-up 30 days and 2-5 years after the surgery primary outcome measure: success rate of endovascular repair for efficacy measurement. secondary outcome measure: 1 year stent related adverse event rate for safety measurement. other outcome measures: 1. efficacy: * 1 year success rate of treatment * 1 year patency rate of branch stent 2. safety: * in-hospital mortality * complication rate of neural system * 1 year dissection or stent related mortality


Eligibility criteria:
inclusion criteria: * age from 18 to 80, male or unpregnant female * diagnosed as aortic dissection * proximal tear of the dissection locates between 15mm to the distal end of left common carotid artery and 20mm to the distal end of left subclavian artery (lsa) or inverse tear to lsa * good compliance with the instructions and cooperate with follow-up * voluntarily signed the informed consent form exclusion criteria: * pregnant female * no appropriate vessel approaches * patients with connective tissue diseases (such as marfan syndrome) * allergic to nitinol or contrast medium * bad compliance with the instructions and follow-up * estimated remaining life is less than 12 months

Keywords: single-branched stent graft system aortic dissection endovascular repair
core body temperature measurement during hot and cold environmental exposure

Conditions: Body Temperature; Hypothermia

Summary: accurate measurement of core body temperature at the scene of an accident is critical for both diagnosis and treatment/triage decisions for hypothermic patients. measurement in the lower third of the oesophagus is considered the gold standard of ct reading, but invasive and hardly applicable with a conscious patient. tympanic membrane sensors for ct reading have been widely tested by may be unreliable in extreme environmental temperatures. similarly, the double sensor device is a non-invasive device and is promising for prehospital use but has not been sufficiently verified under very cold and hot environmental conditions. furthermore, comparisons of different non-invasive methods with oesophageal measurement in extreme conditions are lacking. the objective of these studies is to compare different techniques of core body temperature measurement with exposure to cold and hot environments.


Eligibility criteria:
inclusion criteria: * \>18 years old * asa class 1 exclusion criteria: * \<18 years old * american society of anesthesiologists class \>1 * history of ear, nose, throat surgery * congenital malformation of head/throat/ear/nose * absence of informed consent
safety of gadovist in renally impaired patients

Conditions: Fibrosis; Renal Impairment

Summary: patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (mri) scan and injection with a contrast agent, gadovist, will be asked to participate. the administration of contrast agents that contain gadolinium such as gadovist might increase a potential risk to develop a rare condition called nephrogenic systemic fibrosis (nsf) in patients with renal impairment. this study is to assess the potential risk to develop nsf in patients with renal impairment after the administration of gadovist. patients who are enrolled in this study will receive a gadovist enhanced mri scan which was prescribed by the referring doctor. after the mri scan the patient will be included in a two year follow-up period to assess if signs or symptoms suggestive of nsf have appeared.


Eligibility criteria:
inclusion criteria: * patients with moderate (egfr 30 - 59 ml/min/173m2) or severe (egfr \< 30 ml/min/1.73m2) renal impairment, scheduled to undergo gadovist-enhanced mri exclusion criteria: * gbca-enhanced mri (or administration of a gbca for any other ce imaging procedure) other than gadovist within 12 months prior to administration of gadovist * history of nsf (nephrogenic fibrosing dermopathy) * age outside the indicated age range mentioned in national labelling.